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Abstract
Introduction We have previously linked HER4 expression with
increased survival in breast cancer. However, other reports have
associated HER4 with adverse prognostic significance. One
possible explanation for the conflicting reports may be that these
results are antibody dependent. The HER4 protein is
enzymatically cleaved, which may alter the function of its
intracellular domain (ICD). We have therefore compared the
staining patterns of antibodies against its intracellular and
extracellular domains using tissue microarray technology.
Methods Immunohistochemistry was performed and evaluated
on tumours from 402 tamoxifen treated oestrogen receptor
positive patients. The HFR1 antibody recognises the ICD of
HER4 and thus recognises both the intact receptor and the
cleaved ICD. The H4.77.16 clone recognises an extracellular
domain of HER4 and thus detects the full length receptor only.
Results Both antibodies demonstrated nuclear, cytoplasmic
and membranous staining. Concordance between the
membrane staining patterns was high (88.44%, kappa 0.426).
The HFR1 antibody, however, demonstrated generally higher
levels of cytoplasmic staining (concordance 74.77%, kappa
0.351). The antibodies demonstrated very different patterns of
nuclear staining. Over 60% of patients stained with the
H4.77.16 had no nuclear staining whereas the vast majority
showed staining with the HFR1 antibody (concordance
40.12%, kappa 0.051). Neither antibody demonstrated
relationships between membranous or cytoplasmic HER4
staining and survival, although associations were seen with
known poor prognostic markers. Cases with H4.77.16-
determined nuclear staining had significantly poorer survival
outcomes.
Conclusion The difference in antigen site may explain the
different staining patterns we have seen with respect to location;
with each antibody appearing to select for distinct
compartments. Thus, HFR1 may select for cytoplasmic and
nuclear HER4 ICD, whilst H4.77.16 selects for membranous
HER4 and/or HER4 being recycled in cytoplasm or nucleus.
This ability to distinguish between site and function of HER4 and
its fragments is particularly important, with recent evidence
highlighting the different functions of nuclear and mitochondrial
HER4.
Introduction
Overexpression of members of the human epidermal growth
factor receptor (HER) family has been widely studied in breast
cancer. Whereas the biology underlying the role of HER2 and
epidermal growth factor receptor (EGFR) has been increas-
ingly documented, more confusion exists in establishing a role
for HER4 (c-erbB-4). We have shown that, in contrast to other
HER family members, HER4 expression is associated with
increased survival and lower proliferation indices [1,2]. These
results are supported by data linking HER4 to established
good prognostic indicators such as a lower grade of tumour
[3,4], oestrogen receptor (ER) positivity [5] and low prolifera-
tion indices [6]. However, whilst other groups have also dem-
onstrated a link between HER4 positivity and a longer disease
free interval [7], conflicting reports have associated HER4 with
an adverse prognostic significance [8]. More recently, evi-
dence from a large series of patients has suggested that the
prognostic value of HER4 overexpression is dependent on
coexpression with other HER family members [9]. In this study,
when the group was looked at as a whole, HER4 status was
not related to survival [9]. In cases showing expression of one
family member only (homodimers), however, they found a sig-
BH3 = BCL-2 homology 3 domain; EGFR = epidermal growth factor receptor; ER = oestrogen receptor; HER = human epidermal growth factor 
receptor; ICD = intracellular domain; SD = standard deviation; TACE = TNFα-converting enzyme; TMA = tissue microarray.Breast Cancer Research    Vol 8 No 2    Tovey et al.
Page 2 of 8
(page number not for citation purposes)
nificant association between HER4 homodimer-expressing
tumours and improved disease free survival.
There are intrinsic problems in comparing these studies and
their outcomes. Different cut off points for positivity have been
chosen depending on the study and the modality of staining
looked at (membrane, cytoplasm and nuclear). Some groups
have reported staining in all three locations, whilst others have
found no membranous [8] or no nuclear staining [7]. Three dif-
ferent antibodies have been used in these studies. The HFR1
clone developed by the Gullick group has been the most
widely used [3,4,8-10]. This group demonstrated the ability of
this antibody to recognise HER4 by immunoprecipitation,
western blotting and immuno-staining of NH3T3 cells trans-
fected with HER4. They demonstrated no cross-reactivity with
EGFR using A431 cell lysates or with HER3 or HER4 using
lysates from SKBR3 or 293/HER3 cells. A Santa Cruz anti-
body C18 has also been used by one group [7]. In our previ-
ously study on frozen tissue, we used a Neomarkers antibody
H4.77.16 [1].
Recent studies have substantially enhanced our understand-
ing of the many functions of HER4. Indeed, as well as acting
as a membrane signal transduction receptor, nuclear HER4 is
required for mammary gland development and lactation
through gene regulation in conjunction with STAT5A [11,12],
and mitochondrial HER4 has been shown to mediate apopto-
sis in the mitochondria via BAK [13].
Recent evidence suggests that, as with HER2 and EGFR, the
HER4 protein can be enzymatically cleaved, which may mark-
edly alter the function of the intracellular domain of the recep-
tor. Cleavage occurs within the juxtamembrane region through
the activity of tumour necrosis factor-α-converting enzyme
(TACE) followed by further proteolysis processing by preseni-
lin-dependent  γ-secretase activity [14,15] to release the
cleaved intracellular domain (4ICD). Indeed, this 4ICD has
been shown to harbour a BCL-2 homology 3 (BH3) domain
and can independently function as a BH3-only protein (pro-
apoptotic members of the BCL-2 family required to initiate
mitochondria dysfunction), so mediating cellular apoptosis
[13]. However, it has also been demonstrated in the nucleus
acting as a chaperone for STAT5A [12] to alter gene regula-
tion. Thus, it is essential to determine both the location and
intensity of staining for HER4 in order to fully understand its
function in vivo. The variance in reported results for in vivo
analysis of HER4 expression may be a reflection of differing
antibody specificities, especially with respect to the intracellu-
lar and extracellular domains of the protein. Indeed, one recent
study using the HFR1 antibody demonstrated very different
correlations in terms of survival depending on cellular location
of HER4 staining. Whilst membranous HER4 was associated
with a good prognostic outlook, nuclear HER4 was associated
with significantly shorter survival times [16].
Thus, one possible explanation for the conflicting reports on
HER4 and its association with survival may be that the results
are antibody dependent. HFR1 recognises the intracellular
domain of HER4 and is thus able to recognise both the intact
receptor and the cleaved ICD as it traffics through the cell.
However, the H4.77.16 clone recognises an extracellular
domain of HER4 and thus, on tissue sections, detects the full
length receptor, not the cleaved ICD. We have therefore com-
pared the staining patterns of these most widely used antibod-
Table 1
Patient clinical and pathological variables
Variable Number/total Valid (%)
Grade
1 99/391 25.32
2 193/391 49.36
3 99/391 25.32
Unknown 11
Nodal status
0 193/369 53.1
1–3 107/369 29.1
4+ 69/369 17.8
Unknown 33
Histological type
Ductal 322/397 80.1
Lobular 45/397 11.6
Other 30/397 8.3
Unknown 5
Size
T1 (<20 mm) 154/380 40.53
T2 (20–50 mm) 204/380 53.68
T3 (>50 mm) 22/380 5.79
Unknown 22
NPI
<3.5 128/344 37.21
3.5–5.5 106/344 30.81
5.5+ 110/344 31.98
Missing 58
Age
<50 years 73/402 36.5
>50 years 328/402 63.5
Grade is the Bloom and Richardson grade. Nodal status is the 
number of positive nodes. Pathological type: ductal, invasive ductal 
carcinoma; lobular, invasive lobular carcinoma; other includes 
mucinous, mucoid and so on. NPI, Nottingham Prognostic Index 
(grade + nodal status + 0.02 × size in mm).Available online http://breast-cancer-research.com/content/8/2/R19
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ies in standardised conditions in a large cohort of patients
using tissue microarray technology.
Materials and methods
Patients
The local ethics committee granted ethical approval for the
study. Four hundred and two, tamoxifen treated, ER positive
patients, were selected from a database of sequentially diag-
nosed patients presenting with operable breast cancer
between 1980 and 1999 for a retrospective study relating
molecular markers to tamoxifen resistance [17]. They had
standard adjuvant treatment according to protocols at the time
of diagnosis.
Tissue microarray construction
Three 0.6 mm2 cores of breast cancer tissue were removed
from representative tumour areas on each block identified by
a pathologist (BD). These cores were used to construct recip-
ient array blocks in triplicate (80 to 120 cores per block).
Cores of normal skin, smooth muscle, testes, lymph node, pla-
centa and tonsil were also included in the tissue microarray
(TMA) as controls. If one or more core was uninformative
because of loss or lack of tumour in core then the scoring
results were taken from the remaining core(s).
Immunohistochemistry
Sections were de-waxed and hydrated then endogenous per-
oxide was blocked with hydrogen peroxide. There was no anti-
gen retrieval required. Sections were incubated in serum free
block (DAKO UK Ltd, Ely, Cambridgeshire, UK) to block non-
specific background staining then endogenous biotin was
blocked with an Avidin/Biotin blocking agent (Vector Labora-
tories, Peterborough, UK). Incubation with the primary anti-
body diluted in a tris-HCL buffer (DAKO) was performed at
room temperature. The HFR1 antibody was used at a concen-
tration of 4 µg/ml for 2 hours, and the H4.77.16 antibody was
used at a concentration of 50 µg/ml for 2 hours, both at room
temperature. The DAKO LSAB+ kit was used for signal ampli-
fication. Washes, between all steps, were performed with TBS
solution (Tris saline buffer, pH 7.6). Detection was then com-
pleted with incubation with a 3,3'diaminobenzidine (DAB)
solution (Vector) diluted in dH20 for 10 minutes. Finally the
sections were counterstained, dehydrated and mounted. A
control slide was incubated in each run with an isotype
matched control antibody to ensure no false positive staining.
Figure 2
Frequency histograms for membrane staining intensity using (a) H4.77.16 and (b) HFR1 Frequency histograms for membrane staining intensity using (a) H4.77.16 and (b) HFR1.
Figure 1
Photomicrographs of immunohistochemical staining using (a) H4.77.16 and (b) HFR1 antibodies Photomicrographs of immunohistochemical staining using (a) H4.77.16 and (b) HFR1 antibodies.Breast Cancer Research    Vol 8 No 2    Tovey et al.
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All slides for each antibody were stained in a single staining
run to minimise batch to batch variation.
Staining and scoring for HER1, HER2 and HER3 was per-
formed for the same set of patients as described previously
[17].
Scoring
One scorer scored all cases having previously double scored
a series of TMA slides (including the Herceptest and ER
slides) with an experienced diagnostic scorer achieving an
ICCC (intra-class correlation coefficient) of 0.94 (n = 890) for
membrane staining and 0.84 (n = 827) for nuclear staining.
Membrane staining was scored using the Herceptest method.
Cores with over 10% of strong membrane staining were
assigned 3+; cores with over 10% moderate staining were
assigned 2+; and cores with over 10% of cells with incom-
plete membrane staining were assigned 1+. When there was
any discrepancy between cores, the mean percentages
stained at each intensity level were calculated. Thus, an aver-
age of at least 10% of cells with strong membranous staining
over analysed cores would be required for the combined score
to reach 3+. Patients were considered positive for membra-
nous HER4 if they had at least 2+ staining intensity (for
instance, at least 10% of tumour cells were scored as being
moderately positive).
Nuclear and cytoplasmic scoring was performed using the
Histoscore method. This involves giving a weighted score for
percentages of staining seen, where the percentage of cells
stained (0% to 100%) is multiplied by the staining intensity (1,
2 or 3) to give a maximum histoscore of 300. The histoscores
for each core were then averaged. Patients were considered
positive for cytoplasmic or nuclear HER4 if the average histo-
score for the respective modality was greater than 10.
Statistical analysis
The statistical software package SPSS version 9.0 (SPSS
Inc., Chicago, IL) was used for all analysis. The Kaplan Meier
life table statistical analysis was undertaken for disease free
and survival analysis. Concordance between two antibodies,
with regard to staining at the membrane, cytoplasm and
nucleus, was evaluated using chi-square kappa values, where
a value of 1 indicates perfect agreement and a value of 0 indi-
cates that agreement is no better than chance. Correlations
with clinicopathological variables and other HER family mem-
bers were performed using Chi-square or Fishers test.
Results
Patient characteristics
Clinical and pathological characteristics, including grade,
nodal status, histology, size, Nottingham Prognostic Index and
age are shown in Table 1. In addition to tamoxifen, 99/399
(24.8%) patients had chemotherapy (3 unknown) and 110/
Table 2
Comparison of H4.77.16 and HFR1 staining patterns in the membrane, cytoplasm and nucleus
H4.77.16 Kappa value
Negative Positive Total
Membrane 0.426 (p < 0.001)
H F R 1 N e g a t i v e 2 7 32 83 0 1
Positive 10 18 28
Total 283 46 329
Cytoplasmic 0.351 (p < 0.001)
HFR1 Negative 41 15 56
Positive 68 205 273
Total 109 220 329
Nuclear 0.051 (p < 0.018)
HFR1 Negative 21 3 24
Positive 194 111 305
Total 215 114 329
Chi-square where numbers of cases negative or positive for each antibody at the membrane, cytoplasm or nucleus are shown using cut offs 
defined in the text. Cohen's Kappa value measures the agreement between the two antibodies, where a value of 1 indicates perfect agreement 
and a value of 0 indicates agreement is no better than chance.Available online http://breast-cancer-research.com/content/8/2/R19
Page 5 of 8
(page number not for citation purposes)
399 (27.57%) had radiotherapy (3 unknown). The median
duration of tamoxifen therapy was 5 years. The mean follow-up
duration is 6.91 years (standard deviation (SD) 3.34 years)
and median 6.45 years (range 0.64 to 18.42 years).
Missing cores
For the H4.77.16 and HFR1 antibodies there were 61/402
(15.2%) and 43/402 (10.7%) cases, respectively, with no
valid cores available for analysis. This was due to a combina-
tion of either core loss or because no tumour was present
within the core.
Comparison of antibody staining patterns: membrane, 
cytoplasm and nuclear
Both antibodies demonstrated nuclear, cytoplasmic and mem-
branous staining (Figure 1a, b). Membrane staining patterns
for each antibody are shown (Figure 2a, b). Using the cutoffs
previously described, 46/341 (11.4%) patients were classed
as positive using the H4.77.16 antibody and 28/359 (7.0%)
using the HFR1 antibody.
The concordance between membrane staining using the 2
antibodies is 88.44% (n = 329; Table 2) with a kappa value of
0.426 (where a value of 1 indicates perfect agreement and a
value of 0 indicates that agreement is no better than chance).
It can be seen in Figure 2 that the percentage of tumours that
are negative is similar between the two antibodies but that the
H4.77.16 antibody appears to detect a stronger intensity of
staining at the membrane. This may reflect a difference in sen-
sitivity between the antibodies or, alternatively, a difference
between TACE cleaved but γ-secretase intact HER4.
The median cytoplasmic histoscore for H4.77.16 antibody
was 36.67 (range 0 to 250) and mean 48.21 (SD 50.32). The
median cytoplasmic histoscore for HFR1 was 75 (range 0 to
253) and mean 78.75 (SD 61.10). The HFR1 antibody there-
fore generally has higher levels of cytoplasmic staining (Figure
3a, b). Using the cut offs described previously (histoscore
>10), 225/341 (66.0%) tumours were classed as positive
using the H4.77.16 antibody and 293/359 (81.6%) using the
HFR1 antibody. The concordance between the 2 antibody
results is 74.77% (n = 329; Table 2) with a kappa value of
0.351. This difference may reflect the fact that HFR1 can rec-
ognise both cleaved 4ICD and the intact (recycling) HER4,
whilst H4.77.16 recognises the intact form only.
The median nuclear score for H4.77.16 antibody was 0 (range
0 to 200) and mean 15.01 (SD 26.42). The median nuclear
score for HFR1 was 63.33 (range 0 to 200) and mean 64.83
(SD 38.65). The antibodies showed very different staining pat-
terns in the nucleus (Figure 4a, b). Using the cut offs
described previously (histoscore >10), 116/341 (34.0%)
patients were classed as positive using the H4.77.16 antibody
and 332/359 (89.3%) using the HFR1 antibody. Whilst over
60% of patients stained with the H4.77.16 had no nuclear
staining, the vast majority showed some staining with the
HFR1 antibody. Once split into positive and negative groups,
the concordance between the 2 antibody results is 40.12% (n
= 329; Table 2) with a kappa value of 0.051. This lack of
agreement may well reflect the fact that the cleaved 4ICD (rec-
ognised by HFR1) is much more likely to be found in the
nucleus than the intact form.
Relationship between staining locations for each 
antibody
Staining patterns using the H4.77.16 antibody showed corre-
lations between membranous staining and both cytoplasmic
and nuclear staining (both p < 0.001, Mann Whitney). How-
ever, whilst there was a correlation between membranous and
cytoplasmic staining using the HFR1 antibody (p = 0.008,
Mann Whitney), there was no correlation between membra-
nous and nuclear staining (p = 0.259, Mann Whitney).
Table 3
Membranous HER4: correlation with pathological variables and HER family
H4.77.16 HFR1
χ2 P value Correlation χ2 P value Correlation
NPI 4.799 0.091 6.095 0.047 Positive
Size 8.652 0.013 Positive 8.608 0.008 Positive
Grade 2.453 0.293 0.75 0.687
Nodal 1.769 0.413 3.202 0.202
EGFR Fishers 0.019 Positive Fishers 0.074
HER2 1.657 0.243 Fishers 0.314
HER3 53.67 <0.001 Positive Fishers <0.001 Positive
Grade is the Bloom and Richardson grade. Nodal status is the number of positive nodes. NPI, Nottingham Prognostic Index (grade + nodal status 
+ 0.02 × size in mm). EGFR, epidermal growth factor receptor.Breast Cancer Research    Vol 8 No 2    Tovey et al.
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Relationship with clinicopathological variables and the 
other HER family members
We have previously reported the HER1-3 status of this cohort
[17]; 6/393 (1.5%) patients are positive for HER1, 51/397
(12.8%) positive for HER2 and 56/353 (15.9%) are positive
for HER3. Altogether, 98/350 (28.0%) cases are positive for
one or more of HER1, HER2 or HER3.
Both antibodies demonstrated a significant relationship
between membranous HER4 and increasing size and HER3
positivity (Table 3). For the patients positive for HER4 using
the HFR1 antibody, 22/28 (78.57%) were also positive for
another member of the HER family. For the H4.77.16 antibody,
this figure was 28/46 (60.87%).
Both antibodies showed a correlation between HER4 cyto-
plasmic staining and increasing Nottingham Prognostic Index,
nodal status, size and HER3 positivity (Table 4). Neither anti-
body showed any significant correlations between nuclear
HER4 staining and pathological variables or HER1-3 status.
Survival and disease free analysis
For both antibodies there was no relationship between dis-
ease free or overall survival and membranous HER4 staining.
Cases who were positive for HER4 only (and not for any other
members of the HER family) were identified (n = 6 for HFR1
and n = 18 for H4.77.16) but these patients again did not have
significantly different rates of survival. Cytoplasmic staining
was not correlated with disease free or overall survival using
either antibody. However, cases demonstrating nuclear HER4
staining using the H4.77.16 antibody were significantly more
likely to have poorer overall survival (p = 0.0124, Figure 5).
There was no such correlation with survival with the HFR1
antibody.
Discussion
We have demonstrated for the first time that the H4.77.16
antibody can be used successfully in formalin fixed tissue. In
keeping with previous reports we also have found membra-
nous, cytoplasmic and nuclear staining. The HFR-1 antibody is
raised against an intracellular epitope aa1249-1264 (there-
fore, it will detect both the intact and cleaved form of 4ICD)
Figure 4
Frequency histograms for nuclear staining intensity using (a) H4.77.16 and (b) HFR1 Frequency histograms for nuclear staining intensity using (a) H4.77.16 and (b) HFR1.
Figure 3
Frequency histograms for cytoplasmic staining intensity using (a) H4.77.16 and (b) HFR1 Frequency histograms for cytoplasmic staining intensity using (a) H4.77.16 and (b) HFR1.Available online http://breast-cancer-research.com/content/8/2/R19
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whilst the H4.77.16 antibody is raised against an extracellular
fragment (hence will detect only the full length HER4 protein
or the cleaved extracellular domain at the cell surface). This dif-
ference in antigen site may explain the different staining pat-
terns we have seen in terms of location, with each antibody
appearing to select for distinct compartments. Thus, HFR1
may select for cytoplasmic and nuclear HER4 ICD whilst
H4.77.16 selects for membranous HER4 and possibly also
HER4 being recycled in cytoplasm or nucleus. This ability to
distinguish between site and function of HER4 and its frag-
ments is particularly important with recent evidence highlight-
ing the different functions of nuclear and mitochondrial HER4.
We now know that whilst HER4 at the membrane is account-
able for signal transduction, mitochondrial HER4 ICD appears
to be involved in apoptosis mediation [13] and nuclear HER4
is required for mammary gland development and lactation
[11].
Despite the differences seen in staining location, we demon-
strate that in terms of relationships with pathological variables,
HER family members and prognostic importance, when tested
under standardised conditions on the same set of tumours
both antibodies provide generally similar results. The excep-
tion to this is the association that H4.77.26-detected nuclear
HER4 has with poorer survival. This correlates with recently
published results demonstrating that whilst membranous
HER4 was associated with a good prognostic outlook, nuclear
HER4 was associated with significantly shorter survival times
[16]. Interestingly, this study also used the H4.77.16 antibody.
Clearly this demonstrates that despite strong evidence for the
role of the cleaved 4ICD, intact HER4 may also have a signifi-
cant nuclear function.
We have not demonstrated any association between membra-
nous HER4 and survival when considered alongside other
HER family members or alone. However, we did demonstrate
an association between membranous and cytoplasmic HER4
and known poor prognostic variables. Few cases in this series
expressed HER4 in isolation and it is increasingly apparent
that co-expression of HER4 with other HER proteins may
abrogate its protective effects [9]. HER4 appears, therefore,
to be protective if homodimerisation occurs, but this effect is
lost if other HER members are activated by heterodimerisation
with HER4. This is also consistent with data from cell lines
showing that whilst HER4 can induce growth arrest and differ-
entiation [18,19], when co-expressed with other receptors,
such as HER2 and HER3, signalling through these receptors
Figure 5
Cumulative survival differences between patients positive or negative  for nuclear HER4 using the H4.77.16 antibody Cumulative survival differences between patients positive or negative 
for nuclear HER4 using the H4.77.16 antibody. Kaplan-Meier survival 
curves demonstrating cumulative survival differences (endpoint breast 
cancer related death) between patients positive or negative for nuclear 
(nuc) HER4 using the H4.77.16 antibody. P values represent log rank 
testing of the difference in cumulative disease free survival.
Table 4
Cytoplasmic HER4: correlation with pathological variables and HER family
Test H4.77.16 histoscore HFR1 histoscore
P value Correlation P value Correlation
NPI Kendall's tau-b 0.004 Positive <0.001 Positive
Size Kendall's tau-b <0.001 Positive 0.021 Positive
Grade Kendall's tau-b 0.076 <0.001 Positive
Nodal Kendall's tau-b 0.004 Positive <0.001 Positive
EGFR Mann-Whitney 0.035 0.436
HER2 Mann-Whitney 0.381 0.771
HER3 Mann-Whitney <0.001 Positive 0.001 Positive
Grade is the Bloom and Richardson grade. Nodal status is the number of positive nodes. NPI, Nottingham Prognostic Index (grade + nodal status 
+ 0.02 × size in mm). EGFR, epidermal growth factor receptor.Breast Cancer Research    Vol 8 No 2    Tovey et al.
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promotes proliferation and overrides the effects seen when
HER4 is expressed in isolation [20]. However, the exact mech-
anism of this HER4 mediated effect remains unclear; our data
links HER4 to low proliferative indices [2] but HER4 is also
linked to apoptosis [13]. Coexpression of other HER family
members may, therefore, explain some of the conflicting
reports on survival both here and in published studies.
In addition, this cohort of patients is a tamoxifen treated group,
the majority of which are ER positive. Previous studies, includ-
ing ours, have suggested a greater tendency for HER4 to be
associated with ER positive tumours [5,21,22]. Within this
generally less aggressive set of cancers, the effect of HER4
may be less pronounced.
Conclusion
We have demonstrated that antibodies against two different
HER4 receptor antigen sites identify clear differences in stain-
ing patterns. The differences in published reports may well
reflect the differing abilities of antibodies to detect distinctly
different HER4 functions. The ability of TACE and presenilin to
cleave HER4 and modify its activity suggest that careful atten-
tion to the subcellular localisation of both cleaved and intact
HER4 is essential when investigating its mechanisms of
action. It is possible that antibodies more specifically targeting
the TACE or BH3 domain may prove valuable in further eluci-
dating the functions of HER4, particularly in regard to impact
on clinical outcome in breast cancer.
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